ObsEva Announces Positive Results from Uterine Fibroids Phase 3 Study (PRIMROSE 2) of Linzagolix Phase 3 trial (PRIMROSE 2) met primary and secondary efficacy endpoints93.9% responder rate for 200 mg with ABT (p < 0.001)56.7% responder rate for 100 mg without ABT (p < 0.001)Both doses...

ObsEva SA to Hold Conference Call to Discuss PRIMROSE 2 Trial Results on December 9, 2019   Geneva, Switzerland and Boston, MA –December 6, 2019 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s...

ObsEva SA Announces Completion of Patient Recruitment in PRIMROSE 2 Phase 3 Clinical Trial of Linzagolix for the Treatment of Heavy Menstrual Bleeding Associated with Uterine Fibroids Geneva, Switzerland and Boston, MA – December 21, 2018 – ObsEva SA (NASDAQ: OBSV), a clinical- stage biopharmaceutical company focused on the development and commercialization of novel therapeutics...